Scott A. Gruber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Scott A. Gruber has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Katherina Morawski
Section of Transplant Surgery, Department of Surgery, Wayne State University School of Medicine, Detroit, MI
7 shared publicationsMiguel S. West
Section of Transplant Surgery, Department of Surgery, Wayne State University School of Medicine, Detroit, MI
7 shared publicationsMona D. Doshi
Division of Nephrology, Department of Medicine, Wayne State University School of Medicine, Detroit, MI
6 shared publicationsAtul Singh
Division of Nephrology, Department of Medicine, Wayne State University School of Medicine, Detroit, MI
5 shared publicationsElizabeth Cincotta
Pharmacy Department, Harper University Hospital, Detroit, MI
5 shared publicationsJose M. El-Amm
4 shared publications
Latest Publications
- 28 July 2009
- Published by Wiley in Clinical Transplantation
- Vol. 23 (4) , 454-461
Outcome predictors in African‐American deceased‐donor renal allograft recipients
Abstract: The relative importance of donor and recipient risk factors in predicting outcomes in African‐American (AA) renal allograft recipients receiving contemporary immunosuppression, including early steroid withdrawal, has not been previously examined. We assessed the impact of 21 risk factors on five primary outcomes in 132 deceased‐donor AA renal allograft recipients transplanted from July 2001 to August 2006 with follow‐up 6–67 (mean 35 ± 17) months by univariate and multivariate analysis. Thymoglobulin or basiliximab was given for induction, and mycophenolate mofetil with either tacrolimus or sirolimus (SRL) ± prednisone for maintenance. Non‐compliance accounted for 26% of graft loss (GL) and 19% of acute rejection (AR) episodes, and was more prevalent in patients who were HCV+ and those on prednisone. Delayed graft function remained a significant predictor of GL, but not via increased AR, and donor ethnicity emerged as an important predictor of patient death. De novo use of SRL resulted in increased AR, and only increased recipient age significantly predicted new‐onset diabetes mellitus. Our preliminary results suggest the need for improvements in patient education, pre‐transplant psychosocial assessment, and late post‐transplant psychosocial support and can be utilized to help guide donor/recipient selection and tailor immunosuppressive management to optimize outcomes in this challenging group of patients.
- 28 July 2009
- Published by Wiley in Clinical Transplantation
- Vol. 23 (4) , 454-461
Outcome predictors in African‐American deceased‐donor renal allograft recipients
Abstract: The relative importance of donor and recipient risk factors in predicting outcomes in African‐American (AA) renal allograft recipients receiving contemporary immunosuppression, including early steroid withdrawal, has not been previously examined. We assessed the impact of 21 risk factors on five primary outcomes in 132 deceased‐donor AA renal allograft recipients transplanted from July 2001 to August 2006 with follow‐up 6–67 (mean 35 ± 17) months by univariate and multivariate analysis. Thymoglobulin or basiliximab was given for induction, and mycophenolate mofetil with either tacrolimus or sirolimus (SRL) ± prednisone for maintenance. Non‐compliance accounted for 26% of graft loss (GL) and 19% of acute rejection (AR) episodes, and was more prevalent in patients who were HCV+ and those on prednisone. Delayed graft function remained a significant predictor of GL, but not via increased AR, and donor ethnicity emerged as an important predictor of patient death. De novo use of SRL resulted in increased AR, and only increased recipient age significantly predicted new‐onset diabetes mellitus. Our preliminary results suggest the need for improvements in patient education, pre‐transplant psychosocial assessment, and late post‐transplant psychosocial support and can be utilized to help guide donor/recipient selection and tailor immunosuppressive management to optimize outcomes in this challenging group of patients.
- 27 July 2008
- Published by Wolters Kluwer Health in Transplantation
- Vol. 86 (2) , 269-274
Preliminary Experience With Renal Transplantation in HIV+ Recipients: Low Acute Rejection and Infection Rates
Only four centers have reported their results with renal transplantation in human immunodeficiency virus (HIV)+ recipients on highly active antiretroviral therapy, and acute rejection (AR) rates have consistently ranged from 43% to 67%. We examined the outcomes of eight adult HIV+ primary renal allograft recipients with median 15 (range 8-47) months follow-up with multiple other high-risk factors, including African American ethnicity, hepatitis C virus (HCV) positivity, long waiting times, prior sensitization, paucity of live donors, and delayed graft function. Our immunosuppressive protocol consisted of an anti-interleukin-2 receptor antibody for induction, and mycophenolate mofetil, cyclosporin A, and prednisone for maintenance. Initial and 3- to 6-month cyclosporin A trough level targets were 250 to 300 and 225 to 275 ng/mL, respectively, and mycophenolate mofetil dose was adjusted according to 2 to 4 week surveillance and subsequent as needed mycophenolic acid predose concentrations during the first 6 months. Patient and graft survival were 100% and 88%, respectively, with an AR rate of 13% and excellent renal function. No patients developed new-onset diabetes, opportunistic or other serious infections, malignancy, or progression of hepatitis C virus-related liver disease. Excellent suppression of HIV replication with maintenance of CD4 counts was noted in all cases. Our findings suggest that HIV+ patients on highly active antiretroviral therapy can undergo successful renal transplantation with a low incidence of both AR and AIDS-associated and non-AIDS associated infections, despite associated risk factors for poorer outcome. Our encouraging but preliminary results with this protocol will need to be verified in larger numbers of HIV+ renal allograft recipients with longer follow-up.
- 27 July 2008
- Published by Wolters Kluwer Health in Transplantation
- Vol. 86 (2) , 269-274
Preliminary Experience With Renal Transplantation in HIV+ Recipients: Low Acute Rejection and Infection Rates
Only four centers have reported their results with renal transplantation in human immunodeficiency virus (HIV)+ recipients on highly active antiretroviral therapy, and acute rejection (AR) rates have consistently ranged from 43% to 67%. We examined the outcomes of eight adult HIV+ primary renal allograft recipients with median 15 (range 8-47) months follow-up with multiple other high-risk factors, including African American ethnicity, hepatitis C virus (HCV) positivity, long waiting times, prior sensitization, paucity of live donors, and delayed graft function. Our immunosuppressive protocol consisted of an anti-interleukin-2 receptor antibody for induction, and mycophenolate mofetil, cyclosporin A, and prednisone for maintenance. Initial and 3- to 6-month cyclosporin A trough level targets were 250 to 300 and 225 to 275 ng/mL, respectively, and mycophenolate mofetil dose was adjusted according to 2 to 4 week surveillance and subsequent as needed mycophenolic acid predose concentrations during the first 6 months. Patient and graft survival were 100% and 88%, respectively, with an AR rate of 13% and excellent renal function. No patients developed new-onset diabetes, opportunistic or other serious infections, malignancy, or progression of hepatitis C virus-related liver disease. Excellent suppression of HIV replication with maintenance of CD4 counts was noted in all cases. Our findings suggest that HIV+ patients on highly active antiretroviral therapy can undergo successful renal transplantation with a low incidence of both AR and AIDS-associated and non-AIDS associated infections, despite associated risk factors for poorer outcome. Our encouraging but preliminary results with this protocol will need to be verified in larger numbers of HIV+ renal allograft recipients with longer follow-up.
- 29 February 2008
- Published by Elsevier in Journal of Surgical Research
- Vol. 144 (2) , 357
QS226. Preliminary Experience With Renal Transplantation in HIV+ Recipients
- 29 February 2008
- Published by Elsevier in Journal of Surgical Research
- Vol. 144 (2) , 357
QS226. Preliminary Experience With Renal Transplantation in HIV+ Recipients
- 30 June 2007
- Published by Wiley in Clinical Transplantation
- Vol. 21 (4) , 466-471
Sirolimus exposure during the early post‐transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients
Abstract: Introduction: There are limited data regarding the role of individual maintenance immunosuppressive agents in the development of cytomegalovirus (CMV) infection. We examined the association between exposure to sirolimus (SRL) and risk of CMV infection after kidney transplantation when compared with tacrolimus (TCL).Methods: This is a retrospective observational study of adult renal allograft recipients transplanted between 2001 and 2005 at our center. Patients received anti‐lymphocyte antibody induction, and mycophenolate mofetil with either SRL or TCL ± prednisone. D+/R− patients received valganciclovir 900 mg/d and CMV + patients 450 mg/d for three months. CMV infection was diagnosed with pp65 antigenemia testing prompted by clinical suspicion.Results: A total of 14 Cases with CMV infection and 129 Controls were identified for primary analysis, and 11 D+/R− Cases and 19 D+/R− Controls for secondary analysis. The groups were comparable in both analyses, except for D+/R− serostatus in the primary analysis. All 14 Cases were on TCL for at least three months prior to diagnosis of CMV infection. In the primary analysis, zero Cases, but 30.2% and 34.9% of Controls (p = 0.009 and 0.004), and in secondary analysis, zero Cases, but 31.6% and 42.1% of Controls (p = 0.046 and 0.013), were on SRL at one and three months, respectively. In the primary analysis, zero Cases vs. 45 Controls (p = 0.004), and in secondary analysis, zero Cases vs. eight Controls (p = 0.013), were on SRL for at least three months early post‐transplantation.Conclusion: These findings suggest that SRL as a component of a multidrug immunosuppressive regimen decreases the risk of CMV infection after kidney transplantation when compared with TCL.
- 30 June 2007
- Published by Wiley in Clinical Transplantation
- Vol. 21 (4) , 466-471
Sirolimus exposure during the early post‐transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients
Abstract: Introduction: There are limited data regarding the role of individual maintenance immunosuppressive agents in the development of cytomegalovirus (CMV) infection. We examined the association between exposure to sirolimus (SRL) and risk of CMV infection after kidney transplantation when compared with tacrolimus (TCL).Methods: This is a retrospective observational study of adult renal allograft recipients transplanted between 2001 and 2005 at our center. Patients received anti‐lymphocyte antibody induction, and mycophenolate mofetil with either SRL or TCL ± prednisone. D+/R− patients received valganciclovir 900 mg/d and CMV + patients 450 mg/d for three months. CMV infection was diagnosed with pp65 antigenemia testing prompted by clinical suspicion.Results: A total of 14 Cases with CMV infection and 129 Controls were identified for primary analysis, and 11 D+/R− Cases and 19 D+/R− Controls for secondary analysis. The groups were comparable in both analyses, except for D+/R− serostatus in the primary analysis. All 14 Cases were on TCL for at least three months prior to diagnosis of CMV infection. In the primary analysis, zero Cases, but 30.2% and 34.9% of Controls (p = 0.009 and 0.004), and in secondary analysis, zero Cases, but 31.6% and 42.1% of Controls (p = 0.046 and 0.013), were on SRL at one and three months, respectively. In the primary analysis, zero Cases vs. 45 Controls (p = 0.004), and in secondary analysis, zero Cases vs. eight Controls (p = 0.013), were on SRL for at least three months early post‐transplantation.Conclusion: These findings suggest that SRL as a component of a multidrug immunosuppressive regimen decreases the risk of CMV infection after kidney transplantation when compared with TCL.
- 1 April 2006
- Published by Wolters Kluwer Health in Transplantation
- Vol. 81 (7) , 971-972
Is Age the Only Determinant?
- 1 April 2006
- Published by Wolters Kluwer Health in Transplantation
- Vol. 81 (7) , 971-972
Is Age the Only Determinant?
- 1 March 2005
- Published by Wiley in Clinical Transplantation
- Vol. 19 (2) , 273-278
Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus
- 1 March 2005
- Published by Wiley in Clinical Transplantation
- Vol. 19 (2) , 273-278
Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus